Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer"
Ann Surg
.
2021 Dec 1;274(6):e800-e801.
doi: 10.1097/SLA.0000000000004538.
Authors
Hua-Xiang Xu
1
2
3
4
,
Shuo Li
1
2
3
4
,
Shuai-Shuai Xu
1
2
3
4
,
Liang Liu
1
2
3
4
,
Xian-Jun Yu
1
2
3
4
Affiliations
1
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
2
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
3
Shanghai Pancreatic Cancer Institute, Shanghai, China.
4
Pancreatic Cancer Institute, Fudan University, Shanghai, China.
PMID:
33065647
DOI:
10.1097/SLA.0000000000004538
No abstract available
Publication types
Letter
Comment
MeSH terms
CA-19-9 Antigen*
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms* / therapy
Substances
CA-19-9 Antigen